In recent trading developments, several firms and trusts have either bought, sold, or held their stakes in
Medtronic Plc MDT. RNC Capital Management LLC, Legacy Advisory Services LLC, Ashton Thomas Private Wealth LLC, and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd, were among the institutions accumulating more shares of the company. Meanwhile, Jones Financial Companies Lllp, UBS AM, Geneos Wealth Management Inc. and Gotham Asset Management LLC reduced their positions.
Medtronic also announced
FDA approval of the SmartGuard Algorithm as Automated Glycemic Controller. This approval reflects the company's innovative approach towards acquiring regulatory compliance. Furthermore, Medtronic has reported impressive financial results for
first quarter fiscal 2026, showing strong revenue growth and raised EPS guidance.
The company's shares have been evaluated by experts who have set the price target at $102.14. The financial performance has also projected a positive outlook for the firm, with it potentially outperforming the healthcare sector. Finally, Medtronic has announced its intent to separate MiniMed into a standalone company, with appointments of new board members to strengthen its strategic priorities.
Medtronic Plc MDT News Analytics from Fri, 09 May 2025 07:00:00 GMT to Sun, 14 Sep 2025 00:03:36 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor 2
